StockData

BioMarin Pharmaceutical vs United Therapeutics

BMRN and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BMRN and UTHR compare

United Therapeutics is the larger company, worth 2.2 times as much as BioMarin Pharmaceutical ($25.2B against $11.2B).

On earnings, United Therapeutics is cheaper: it trades at 21.0× trailing earnings, against 153× for BioMarin Pharmaceutical.

BioMarin Pharmaceutical grew revenue faster over the last twelve months (11.2% versus 2.5% for United Therapeutics).

United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 41.6% compared with 2.1% at BioMarin Pharmaceutical.

United Therapeutics scores higher on the StockData Score (11 against 8 for BioMarin Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBMRNUTHR
Size and price
Market cap$11.2B$25.2B
Share price$57.99$587.88
Change, 1 year7.0%27.2%
Change, 5 years−33.8%204%
Beta (5Y)0.390.44
Employees3,2211,400
StockData Score
Total score811 (better)
Valuation score11
Growth score3 (better)2
Performance score25 (better)
Health score23 (better)
Dividend score00
Valuation
P/E153×21.0× (better)
P/S3.3× (better)8.0×
P/B1.8× (better)3.9×
EV/EBITDA48.1×15.1× (better)
P/FCF15.2× (better)23.1×
PEG4.500.92 (better)
FCF yield6.6% (better)4.3%
Fair value$30.23$480.40
Margin of safety−91.8%−22.4% (better)
Growth
Revenue growth (TTM)11.2% (better)2.5%
Revenue growth, 5Y average11.6%16.5% (better)
Net income growth (TTM)−88.9%5.5% (better)
EPS growth (TTM)−88.7%9.0% (better)
EPS growth, 5Y average−16.7%19.3% (better)
Profitability
Gross margin76.1%86.1% (better)
Operating margin4.4%44.4% (better)
Net margin2.1%41.6% (better)
FCF margin21.7%34.6% (better)
Return on equity1.2%19.3% (better)
Return on invested capital1.0%29.7% (better)
Financial health
Debt / equity0.66–
Net debt / EBITDA10.96–
Interest coverage2.0×117× (better)
Current ratio2.395.73 (better)
Altman Z-score1.8521.79 (better)
Piotroski F-score48 (better)
Dividends and buybacks
Buyback yield–9.9%
Shareholder yield0.00%9.9% (better)
Ownership
Held by institutions101%97.4%
Held by insiders0.52%9.1%
Insider net buying, 12 months−$4.3M (better)−$1.4B
Superinvestors holding1–
Short interest, % of float7.3%4.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.